- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Multiplex Ligation Dependent Probe Amplification.
Displaying page 1 of 1.
EudraCT Number: 2015-002069-52 | Sponsor Protocol Number: 4045-301 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) SE (Completed) DE (Completed) FR (Ongoing) ES (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing) BG (Ongoing) PL (Ongoing) IE (Ongoing) DK (Ongoing) GR (Ongoing) NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020069-26 | Sponsor Protocol Number: DMD114044 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy. | |||||||||||||
Medical condition: Duchenne muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) IT (Completed) PL (Completed) CZ (Completed) ES (Completed) NO (Completed) DK (Completed) HU (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024566-22 | Sponsor Protocol Number: DMD114118 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of single subcutaneous injections of GSK2402968 in non-ambulant subject... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002913-12 | Sponsor Protocol Number: M12-895 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplati... | |||||||||||||
Medical condition: BRCA1 or BRCA2 mutation metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) DK (Completed) SK (Completed) FI (Completed) SE (Completed) BE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005040-10 | Sponsor Protocol Number: PRO045-CLIN-01 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:BioMarin Nederland B.V. | |||||||||||||
Full Title: A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of PRO045 in subjects with Duchenne muscular dystrophy | |||||||||||||
Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002076-13 | Sponsor Protocol Number: NS-065/NCNP-01-301 | Start Date*: 2020-03-02 | |||||||||||
Sponsor Name:NS Pharma, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) ES (Ongoing) NL (Ongoing) GR (Completed) IT (Ongoing) NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018412-32 | Sponsor Protocol Number: DMD114117 | Start Date*: 2010-08-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambul... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) FR (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005042-35 | Sponsor Protocol Number: PRO053-CLIN-01 | Start Date*: 2013-08-23 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053)... | |||||||||||||
Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by BMN 053-induced DMD exon 53 skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003653-30 | Sponsor Protocol Number: NS-065/NCNP-01-211 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:NS Pharma, Inc | |||||||||||||
Full Title: A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Compared to Natural History Con... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-005027-16 | Sponsor Protocol Number: NOA-18 | Start Date*: 2020-09-16 | ||||||||||||||||
Sponsor Name:Ruprecht-Karls University Heidelberg Medical Faculty, represented by Heidelberg University Hospital | ||||||||||||||||||
Full Title: Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial | ||||||||||||||||||
Medical condition: WHO grade II or III glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002008-25 | Sponsor Protocol Number: 4053-101 | Start Date*: 2014-09-10 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) o... | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001484-23 | Sponsor Protocol Number: Triple-B | Start Date*: 2013-05-24 | |||||||||||
Sponsor Name:BOOG Study Center | |||||||||||||
Full Title: Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.